MDR-102 (Medeor Therapeutics)

N/A

Report date: 2024/06/11 20:00:08

Base Information

Drug NameMDR-102 (Medeor Therapeutics)

Drug Alias NameAllogeneic HLA-mismatched living-donor hematopoetic stem cell therapyMDR-102

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionCell replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsRejection of renal transplantation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedeor Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedeor Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsRejection of renal transplantation

Other Information

ATC CodeN/A